Mixed
Combining bimagrumab (30 mg/kg IV every 12 weeks) with semaglutide (2.4 mg SC weekly) produces synergistic weight loss and body recomposition, achieving significantly greater fat mass reduction and lean mass preservation than either drug alone.
If you have obesity, combining a muscle-preserving antibody (bimagrumab) with a standard GLP-1 drug (semaglutide) yields significantly more fat loss and better muscle retention than using semaglutide alone. This suggests that targeting muscle preservation directly can enhance the efficacy of standard weight loss therapies.
The LSM change in absolute body weight was greater with the high-dose combination versus semaglutide 2.4 mg (−17.8 kg versus −14.2 kg; P < 0.05)... The LSM percent changes in total body lean mass at week 48 were +1.0% to +1.1% (bimagrumab), −4.7% to −6.9% (semaglutide) and −0.8% to −2.3% (combination)... The bimagrumab 30 mg kg−1 plus semaglutide 1.0 mg group showed the greatest preservation of lean mass among the combination groups.
Why this rating
Randomized, double-blind, placebo-controlled Phase 2 trial with a large sample size (N=507) and robust statistical significance (P < 0.001).
Source
Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial
Steven B. Heymsfield et al. · Nature Medicine · 2026
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →